McKesson Completes European Exit with Norwegian Business Sale

The US healthcare giant McKesson has finalized its departure from the European market, concluding the sale of its Norwegian operations to NorgesGruppen. This transaction, completed yesterday, marks the last phase of a strategic withdrawal first announced in August 2025. The move allows the company to concentrate its capital and operational resources on what it deems more profitable core markets.

In separate news for investors, McKesson’s Board of Directors has declared a regular quarterly cash dividend of $0.82 per share. This payment will be distributed on April 1, 2026, to all shareholders of record as of March 2, 2026.

The company’s management will provide further context on this strategic shift and its financial impact during a conference call scheduled for Wednesday, February 4, 2026. This call will discuss the firm’s results for its third fiscal quarter, with additional details on the Norway transaction and the future corporate direction expected imminently.

Should investors sell immediately? Or is it worth buying McKesson?

Strategic Refocus on High-Growth Sectors

The divestiture of its Norwegian retail and distribution division significantly streamlines McKesson’s portfolio. The strategic objective is to sharpen the company’s focus and direct investment toward key growth platforms. Primary areas of emphasis now include oncology care, multispecialty solutions, and biopharma services.

By streamlining operations—particularly within what was previously categorized under "Other" segments—McKesson aims to bolster its standing in the global pharmaceutical supply chain. The financial implications of this sharpened focus on specialty sectors are anticipated to be clarified in the coming days.